MannKind (NASDAQ:MNKD) reported $12.52 million in sales this quarter. This is a 32.14 percent decrease over sales of $18.44 million the same period last year.
At R&D Day, Alpine Immune Highlights Updates On Autoimmune, Immuno-Oncology Programs
Alpine Immune Sciences Inc (NASDAQ:ALPN) announced clinical updates from ALPN-303 and davoceticept programs. Key highlights from the announcement include: ALPN-303 Well…